In this video on OncoDaily TV, Dr. Sergey Badalyan sits down with Dr. Robert Lentz, Medical Director for Oncology at Natera, to discuss the Natera’s latest gastrointestinal oncology research presented at ASCO 2026 and ESMO GI 2026, the future of precision oncology and personalized cancer care.
The discussion explores how serial ctDNA testing with Signatera is helping personalize treatment decisions for patients with colorectal cancer, by helping oncologists better understand residual disease, treatment response, recurrence risk, and the potential benefit of continuing or changing therapy.
Dr. Lentz explains the newest findings from the GALAXY study, real-world immunotherapy analyses, and research in resected colorectal liver metastases, while discussing what these results could mean for clinical practice and future prospective trials.